(Q34078005)

30 July 2017

1 reference

title

Patient compliance with drug therapy in schizophrenia. Economic and clinical issues (English)

1 reference

30 July 2017

0 references

1 reference

Lindström E

1

1 reference

30 July 2017

Bingefors K

series ordinal

2

1 reference

30 July 2017

publication date

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

106-124

1 reference

Epidemiology of long-term functional psychosis in three different areas in Stockholm County

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Social conditions in a total population with long-term functional psychosis in three different areas of Stockholm County

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cross-national diagnosis of schizophrenia in twins. The heritability and specificity of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Establishment of Diagnostic Validity in Psychiatric Illness: Its Application to Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Do Psychiatric In-Patients Take their Pills?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Review of rapid urine tests for phenothiazine and related drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

ATTITUDE AND DRUG ACCEPTANCE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Compliance with medication regimens for mental and physical disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

A critical evaluation of the methodology of the literature on medication compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Self-efficacy: toward a unifying theory of behavioral change

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Utility of the health belief model in examining medication compliance among psychiatric outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

A psychosocial perspective in the explanation of patients' drug-taking behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

The theory of planned behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

The theory of planned behavior: a review of its applications to health-related behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Asthma education, action plans, psychosocial issues and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

21 January 2018

Compliance in psychoses

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Subjective experiences of clozapine treatment by patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Compliance with depot antipsychotic medication by patients attending outpatient clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Quality of life and new antipsychotics in schizophrenia. Are patients better off?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

The effect of risperidone on cognition in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

A comparison of patients who refuse and consent to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Awareness of illness in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Insight and interpretation of illness in recovery from psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Flexible system criteria in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Awareness of illness in schizophrenia and outpatient treatment adherence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Assessment of insight in psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Technique for training schizophrenic patients in illness self-management: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Compliance therapy in psychotic patients: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cost-effectiveness evaluation of compliance therapy for people with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Post-hospitalization treatment adherence of schizophrenic patients: gender differences in skill acquisition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Community and interpersonal functioning in the course of schizophrenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Responses of schizophrenics to expressions of the fundamental emotions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Social functioning of schizophrenic patients: clinical and research issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Facial expression and emotional face recognition in schizophrenia and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Should schizophrenia be treated as a neurocognitive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cognitive remediation in schizophrenia: is it time yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Olanzapine. A pharmacoeconomic review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cognitive improvement in schizophrenia with novel antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

What is the best maintenance dose of neuroleptics in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Medication compliance among the seriously mentally ill in a public mental health system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Housing instability and homelessness among rural schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

One-year follow-up of secondary versus primary mental disorder in persons with comorbid substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Alternative to mental hospital treatment. II. Economic benefit-cost analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Costs of services for schizophrenic patients in Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Economic outcomes and costs in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

21 January 2018

Costs of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Treatment costs and use of community mental health services for schizophrenia by age cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cost of relapse in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Clinical services research

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Measuring quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Awareness of illness in schizophrenia and schizoaffective and mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Quality of life in schizophrenia: insight and subjective response to neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Self-reported life satisfaction and treatment factors in patients with schizophrenia, major depression and anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cost-effectiveness of mental health care. II. Sex as a parameter of cost in the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Schizophrenic relapse after drug withdrawal is predictable

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Clozapine. A novel antipsychotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Cost Analysis of the Treatment of Schizophrenia in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200018020-00002

From compliance to alliance. A quarter century of research

21 January 2018

1 reference

12 December 2020

From compliance to collaboration in the treatment of schizophrenia.

1 reference

12 December 2020

A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients

1 reference

12 December 2020

The General Practitioner and the Schizophrenic Patient

1 reference

12 December 2020

Quality of life measurement during antipsychotic drug therapy of schizophrenia

1 reference

12 December 2020

Savings in hospital bed-days related to treatment with clozapine.

1 reference

12 December 2020

Predictors of outcome in schizophrenia

1 reference

12 December 2020

Cost-utility analysis in schizophrenia.

1 reference

12 December 2020

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial

1 reference

12 December 2020

Why do schizophrenic patients refuse to take their drugs?

1 reference

12 December 2020

Flupenthixol decanoate--in treatment of out-patients

1 reference

12 December 2020

The role of dosage and plasma levels in neuroleptic relapse prevention

1 reference

12 December 2020

Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight

1 reference

12 December 2020

Economics of schizophrenia.

1 reference

12 December 2020

Important issues in the drug treatment of schizophrenia

1 reference

12 December 2020

Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life

1 reference

12 December 2020

Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.

1 reference

12 December 2020

Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel

1 reference

12 December 2020

Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment

1 reference

12 December 2020

Teaching medication management skills to schizophrenic patients

1 reference

12 December 2020

Psychopathological effects of phenothiazin derivatives "largactil" ("megaphen") in self administration and in patients

1 reference

12 December 2020

The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited

1 reference

12 December 2020

Assertive community treatment and medication compliance in the homeless mentally ill.

1 reference

12 December 2020

[Schizophrenia--how much do we need for the cost of treatment and research?]

1 reference

12 December 2020

Neuroleptics and the neuroleptic-induced deficit syndrome.

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia

1 reference

12 December 2020

A comparison of acceptors and resistors of drug treatment as an adjunct to psychotherapy

1 reference

12 December 2020

Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations

1 reference

12 December 2020

Why people use health services

1 reference

12 December 2020

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.

1 reference

12 December 2020

Health care expenditure on schizophrenia patients in Belgium

1 reference

12 December 2020

Evaluation of the quality of life of the schizophrenic outpatient: a checklist

1 reference

12 December 2020

Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects.

1 reference

12 December 2020

Enhancing treatment with psychotropic medicines

1 reference

12 December 2020

Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study

1 reference

12 December 2020

Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies

1 reference

12 December 2020

Randomised controlled trial of compliance therapy. 18-month follow-up

1 reference

12 December 2020

Treatment of schizophrenia

1 reference

12 December 2020

Medication compliance and health education among outpatients with chronic mental disorders.

1 reference

12 December 2020

Societal and individual determinants of medical care utilization in the United States

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

Clinical management of clozapine patients in relation to efficacy and side-effects

1 reference

12 December 2020

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

12 December 2020

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients

1 reference

12 December 2020

Psychological predictors of insight and compliance in psychotic patients

1 reference

12 December 2020

Schizotypal personality disorder. Chestnut Lodge follow-up study: VI. Long-term follow-up perspectives

1 reference

12 December 2020

Phenothiazine intake and staff attitudes

1 reference

12 December 2020

The prediction of outcome in chronic schizophrenia. IV. The Chestnut Lodge follow-up study

1 reference

12 December 2020

Lay beliefs about schizophrenic disorder: the results of a population survey in Germany

1 reference

12 December 2020

Does community care reduce the need for psychiatric beds for schizophrenic patients?

1 reference

12 December 2020

The natural course of schizophrenia and effective maintenance drug treatment

1 reference

12 December 2020

Annual health outcomes and treatment costs for schizophrenia populations.

1 reference

12 December 2020

Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs.

1 reference

12 December 2020

Subjective response to neuroleptics in schizophrenia

1 reference

12 December 2020

Cost-effectiveness in the treatment of schizophrenia

1 reference

12 December 2020

Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics

1 reference

12 December 2020

Facilitating compliance with antipsychotic medication

1 reference

12 December 2020

Estimation of Drug Rejection by Schizophrenic In-Patients, with Analysis of Clinical Factors

1 reference

12 December 2020

Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: results of a 1-year follow-up

1 reference

12 December 2020

Schizoaffective psychosis. II. Manic, bipolar, and depressive subtypes

1 reference

12 December 2020

Predicting medication noncompliance after hospital discharge among patients with schizophrenia

1 reference

12 December 2020

Economics and schizophrenia: the real cost.

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess?

1 reference

12 December 2020

Side-effects, resistance and dosage deviations in psychiatric outpatients treated with tranquilizers

1 reference

12 December 2020

Health economics and cost implications of anxiety and other mental disorders in the United States.

1 reference

12 December 2020

The role of cognition in the risk--benefit and safety analysis of antipsychotic medication

1 reference

12 December 2020

Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance?

1 reference

12 December 2020

[The family--an underestimated but heavily burdened resource in health care]

1 reference

12 December 2020

Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures

1 reference

12 December 2020

Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors

1 reference

12 December 2020

Discriminating characteristics of suicides. Chestnut Lodge follow-up sample including patients with affective disorder, schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs

1 reference

12 December 2020

Cost Efficiency of Treatments for the Schizophrenic Patient

1 reference

12 December 2020

Causes of death in schizophrenia and manic-depression

1 reference

12 December 2020

Outcome in schizophrenia: beyond symptom reduction.

1 reference

12 December 2020

A behavioural training programme for chronic schizophrenic patients. A three-month randomised controlled trial in Beijing

1 reference

12 December 2020

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

1 reference

12 December 2020

Adherence to antipsychotic medications.

1 reference

12 December 2020

10.2165/00019053-200018020-00002

Identifiers

DOI

0 references

Dimensions Publication ID

1025883089

0 references

1 reference